United States

Adam Lohr

Partner, Life Sciences Senior Analyst

Areas of focus: Life Sciences

ABOUT ADAM

In January 2019, Adam was selected as a senior analyst in RSM’s cutting-edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions influencing middle market leaders. Adam’s focus is on the life sciences industry.  

Summary of experience

Adam has more than 10 years of accounting and finance experience, serving private equity backed and private closely-held companies in the middle market. He focuses on high-growth companies that are globally active in the technology, SaaS and consumer products industries. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their businesses.

Prior to joining RSM, Adam was a manager of assurance and risk advisory services. In addition to leading financial statement audits, he performed fraud investigations, business process analysis, and the development of effective oversight and governance environments. 

Adam is an instructor at the regional and national level, and is well-versed in the application of ASC 606 revenue recognition for the technology and consumer products industries. 

Professional Affiliations and Credentials

  • Certified Public Accountant
  • Certified Fraud Examiner
  • American Institute of Certified Public Accountants

Education

  • Bachelor of Science, business administration, University of Arizona
  • Masters of Accountancy, University of Arizona

Recent Perspectives

ARTICLE

3D printing's use in life sciences is more than masks and ventilators

Surging demand for personal protective equipment has lead to a renewed focus on the potential for 3D printing in the life sciences industry.

Cyberattacks threaten companies researching COVID-19 vaccine

INSIGHT ARTICLE

Cyberattacks threaten companies researching COVID-19 vaccine

More promise, more problems: Cyberattacks threaten life sciences companies researching COVID-19 vaccine.

Policy snapshot: Life sciences

INSIGHT ARTICLE

Policy snapshot: Life sciences

Biden plans to expand Medicare, a move that the Congressional Budget Office estimates would cut drug spending by $450 billion over 10 years.

2020 Election preview: Life sciences

INSIGHT ARTICLE

2020 Election preview: Life sciences

With the election approaching, RSM is looking at the economic stakes and the key issues for the life sciences industry.

INSIGHT ARTICLE

Amid pressure to reshore life science supply chains, challenges abound

We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.

INSIGHT ARTICLE

Remote research: Life sciences adapts to clinical trial disruption

For companies that may have dealt with a lab closure because of the pandemic, Scientist.com allows research to continue.

Life sciences industry outlook

INSIGHT ARTICLE

Life sciences industry outlook

Amid the COVID-19 pandemic, life sciences companies, thrust in the spotlight, are positioned for strong growth.

RECORDED WEBCAST

Strategies for life sciences companies expanding to U.S.

Learn about opportunities for life sciences foreign direct investment (FDI) into the United States with this complimentary webcast.

INSIGHT ARTICLE

Life sciences finance leaders discuss strategies to scale businesses

From contract research organizations to initial public offerings, life sciences finance leaders discuss issues in the bioscience businesses.

VIDEO

Life sciences by the numbers: IPOs, deals, M&A and more

RSM senior industry analyst Adam Lohr shares the latest on deals, going public and more in the biotech, pharma and medical devices sectors.

HOW CAN WE HELP YOU?

To discuss how our team can help your business, contact us by phone 800-274-3978.


CONTACT ADAM

+1 619 641 7343
adam.lohr@rsmus.com
Connect on Linkedin